Autoimmune Neurosensory Hearing Loss (ANSHL) Clinical Trial
Official title:
A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss
This study is an open label proof of concept study of rilonacept for patients with ANSHL
Ten (10) patients in total will be enrolled in this study at Metroplex Clinical Research Center in Dallas, TX. Patients may be identified and referred by local area audiologist. The ANSHL study population will be defined by inclusion and exclusion criteria designed to limit enrollment to individuals with idiopathic, progressive, bilateral sensorineural hearing loss, to ensure appropriate candidates for treatment with study medications, and to identify those with a high likelihood of complying with the study protocol. ;